Let’s try that again

Updated


We’ve all seen the effects of statins; lauded greatly, and oft considered an essential part of preventative cardiovascular therapy. Still, newer agents are on the horizon – and evacetrapib is one of them. Mmmm…bacon…

 

What is evacetrapib? A CETP inhibitor – CETP stands for cholesteryl ester transferase protein, and inhition of these protein leads to significant increases in HDL and decreases in LDL. All good, right? In fact, a similar agent has been studied before – torcetrapib, in the ILLUMINATE trial – and yes, the HDL went up and LDL down. 


But…for some reason many more people died. 1.58 times more people in fact, with some of it due to higher cardiovascular mortality. So was it the drug or the actual CETP inhibition causing the problem? There were probably some off target effects of torcetrapib that clouded the issue. 


Which is where evacetrapib comes in. This trial from JAMA shows that there were beneficial effects from  a cholesterol point of view, but without the increased mortality. 


So, CETP inhibition still may be the future of of lipid lowering therapy – check it out here




Update | check out the HPS study over here, in the Lancet, which looked at the long term safety of statins – a worthwhile read for such a commonly used drug


source JAMA
image markaud

Advertisements

One thought on “Let’s try that again

  1. Pingback: Statins associated with development of diabetes mellitus in post-menopausal women | medjuice

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s